Bioavailability and pharmacokinetics of desmopressin in elderly men.
The bioavailability and pharmacokinetics of desmopressin (Minirin, DDAVP) have been studied in elderly males, aged between 55 and 75 years. In a four-way randomised study, subjects received a dose of desmopressin either intravenously (2 micrograms) or orally (200 micrograms) and either at 11 am or 10 pm. Daytime and night-time urine samples were collected both with and without desmopressin treatment. Intravenous doses of desmopressin were observed to have a longer duration of action than when the dose was given orally. These differences in efficacy may be attributable to differences in the bioavailability of desmopressin after intravenous or oral treatment.
Hougaard
C
C
International Enuresis Research Center, Skejby Hospital, University Hospital of Aarhus, Denmark.
Matthiesen
T B
TB
Rittig
S
S
Djurhuus
J C
JC
D000284:Administration, Oral; D000368:Aged; D001682:Biological Availability; D002940:Circadian Rhythm / Q000187:drug effects*; D018592:Cross-Over Studies; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012076:Renal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016482:Urinalysis; D014554:Urination / Q000187:drug effects* / Q000502:physiology
D012076:Renal Agents; D003894:Deamino Arginine Vasopressin